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Abstract 
This literature review addressed the tried out interventions for the management of oral 
submucous fibrosis. The literature supports the use of several medical interventions, 
including micronutrients, anti-oxidants, proteolytic enzymes, immune modulators (mainly 
steroids), and agents to promote blood flow. However, the numbers of reported randomized 
controlled trials are limited. Therefore, no recommendation can be made for any specific 
intervention. Until now, no single molecular pathway has been identified that is neither 
necessary nor sufficient for the development of fibrosis. This has been a bar for any 
molecular targeted therapies. Because areca nut (an ingredient of betel quid) plays a major 
aetiologic role in the causation of OSF cessation of areca nut use remains pivotal in the 
management of this disorder. 
Introduction 
Studies on the natural history of oral submucous fibrosis (OSF) show that it is an insidious 
fibrotic disorder affecting the entire oral mucosa that progresses with time. Aetiology, 
pathogenesis, clinical presentation and pathology of OSF have been reviewed in three other 
publications on this topic in this series 1. A wide range of treatments have been advocated for 
the treatment of OSF, ranging from habit control (ie cessation of areca nut use), physical 
therapy, to medical and surgical interventions.  Often a combination of these strategies is 
used and so far an evidence-based management has not emerged from these various trials. 
This paper highlights the limitations of these reported therapies and makes recommendations 
for future trials for the management of OSF.   
 
Habit intervention 
Epidemiological data from several populations has confirmed that areca nut is the major 
cause of OSF. Cessation of areca nut consumption by regular users remains the most vital 
step in the management of OSF. Areca nut is the fourth most addictive substance known to 
man and a strong dependency to areca nut by regular users was initially reported following 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
the work of Winstock et al who applied adapted versions of dependence scales that were 
designed for substances other than betel quid such as opioids. 2 Later authors have developed, 
and provided validation for an instrument designed specifically for measuring betel quid 
dependence: the Betel Quid Dependence Scale (BQDS). 3,4,5,6  Chen et al devised a Self-
reported Screening Test for identifying an Areca quid Abuser (SSTAA) among Taiwanese. They 
selected 11 questions for self-rating abuse and a score of 4 or more in these 11 questions identified 
an areca quid abuser. 7 
In a literature search conducted by us no reports were found that looked at the effect of habit 
control ie cessation of areca nut habit alone as a primary intervention. The methodology of 
other interventional studies included the advice to quit the habit, although only few of these 
studies described specific measures for cessation. For example, a study conducted in Sri 
Lanka the subjects were given brief advice on areca nut cessation and dental cleaning at 
baseline to remove staining and then re-examined at follow-up visits for any new staining 8. 
No serum markers for metabolites of areca nut were utilized as evidence of cessation. The 
effect of cessation was neither validated nor measured. One limitation faced by researchers / 
clinicians conducting cessation activities is that no active agent is yet available as a suitable 
replacement product to areca nut to assist users to quit the habit. However, the provision of 
advice and follow up requires a systematic approach by the care givers 
 
Medical interventions 
Many observational or retrospective studies that included a medical intervention for 
the management of OSF are listed in Table 1. Various medical interventions used are 
highlighted and their alleged mechanisms of action are briefly stated. These agents were 
delivered in several modes: orally for systemic absorption, intra-lesionaly, or topically, as 
single agents or as a combination of agents. In summary, 15 studies used a single agent, and 
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the rest studied a combinations of agents. In this review we cite the studies that used the use 
of nutrients, micronutrients and/or anti-oxidants, 21 studies included the use of 
immunomodulatory agents that reduced the inflammatory component, principally injected 
corticosteroids (16 studies). 19 studies included the use of proteolytic enzymes to reduce 
fibrosis of which 7 used  hyaluronidase. Several studies included agents to promote blood 
flow.  
 
Nutritional supplements 
Earlier studies had identified nutritional deficiencies as a potential causative factor in OSF 9 . 
Other reports have shown that many subjects diagnosed with OSF were deficient particularly 
in iron and B vitamins 10. In view of these findings several authors have attempted nutritional 
supplementation as a measure of adjunctive treatment of OSF. Among the supplements used, 
vitamins A, B complex, C and E have been tried alone or in combination with other agents 11, 
12, 13, 14, 15, 16
. The rationale for their use is to correct any deficiency states and promote normal 
cellular processes present in health, to improve the epithelial atrophy noted in OSF, 
particularly the generalized tongue depapillation. Superficial ulceration is often noted in OSF 
subjects and these supplements are thought to improve tissue healing. In a study conducted in 
Pakistan multiple micronutrient supplementation was shown to improve symptoms of OSF 
and mouth opening in an open trial 15. 41% of subjects showed improvement in mouth 
opening. Though symptom improvement was achieved, it is unlikely that nutritional 
supplementation alone contribute to any improvement of fibrosis in this condition. Among 
minerals, zinc,12, 15, 16  magnesium, 15 selenium16, manganese 15, 16 and iron 11 have been tried 
(mostly in combinations of two or more minerals) as therapeutic agents. Zinc may play a role 
in chelating copper and correct the imbalance of excess copper proposed as a causative factor 
1
. Kumar and Sharma have shown a beneficial effect of oral zinc alone in treating OSF12. 
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Anti-oxidants 
One of the pathogenic mechanisms of areca nut has been attributed to the generation of 
reactive oxygen species, free radicals and peroxidases.17 Based on this hypothesis several 
authors have tried various naturally occurring or synthetic anti-oxidants. These include, beta 
carotene , lycopene,  tea pigments, aloe vera , curcumin and spirulina. 
 Beta carotene was used as an antioxidant in one trial arm described by Jirge et al 16. 
Following systemic administration for 15 weeks an improvement of mouth opening by 6.7% 
was recorded. 
Lycopene is a red coloured carotenoid predominantly accumulated in tomatoes as 
well as in other pigment containing vegetables and fruits. Lycopene has been reported to be 
beneficial in the management of other oral potentially malignant disorders eg. oral 
leukoplakia and lichen planus 18,19. The effectiveness of lycopene has been tested in two 
randomized controlled studies. Kumar et al.20 recruited 83 participants who received either 
oral lycopene (n=21; group A), oral lycopene with intralesional corticosteroids (n=19; group 
B) or an oral placebo (n=18; group C). The two-month intervention period was completed by 
58 people.  Objective measurement of mouth opening was reported to be significantly 
improved with an average increase of 3.4mm, 4.6mm and 0mm for groups A, B and C, 
respectively.  The increases were maintained at 3 and 6-months follow-up.  All patients who 
took lycopene reported relief from burning sensations within 2 weeks, whereas only one 
patient from the placebo group reported a similar improvement. One other randomized single 
blind trial testing the effectiveness of lycopene, was conducted in Maharashta, India 21. 92 
participants were enrolled, 46 subjects were given 8 mg lycopene daily and the rest were 
given a placebo tablet for 3 months and followed up for further 2 months. Significant 
improvement was reported in mouth opening, mean (SD) 4.48 mm (3.65) in the lycopene 
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group compared with 1.13 mm (1.6) in the control group, and 31% experienced a complete  
improvement in burning sensation vs 7% in the control group.   
 Tea pigments contain oxidised products of polyphenols, derived from tea leaves. 
Among patients with haematinic deficiencies at baseline when supplemented with tea 
pigments together with vitamins A, B , C and D the authors reported an increased mean 
mouth opening of 7.9 mm in 7/12 OSF patients in China 22. The authors suggested that, in 
addition to their anti-oxidant properties, the tea pigments are likely act by improving the 
microcirculation in these patients. 
 Radix Salviae miltiorrhizae (danshen), the dried root of Salvia miltiorrhiza Bge is 
very important and popular in traditional Chinese medicine. Salvianolic acid B (Sal-B) is the 
most abundant and bioactive member of the hydrophilic components in Danshen. Sal-B 
contains seven phenolic hydroxyls which have been found to be closely related to redox 
potentials and/or antioxidant activities 23. Recently, the efficacy of salvianolic acid B (SA-B) 
combined with triamcinolone acetonide in the treatment of oral submucous fibrosis was 
tested 24. A net gain of mouth opening by 5.5 mm was reported in the SA-B group in 20 
weeks but this relapsed to 3.5 in 44 weeks.  The exact antifibrosis mechanism of SA-B is not 
known. 
Spirulina, a blue green algae rich in carotenoids and other micronutrients which have 
chemopreventive potential was used in combination with other agents to test its effectiveness 
in three  trials 25, 26,27.  In one study, the patients on Spirulina showed significant clinical 
improvement in mouth opening and ulcers/erosions/vesicles compared to topical aloe vera 25,  
in reducing burning sensation compared with pentoxyfilline 26, and in both mouth opening 
and burning sensation compared with biweekly intralesional steroid injection of 
Betamethasone (4 mg/ml for 3 months) 27.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
 In a randomised controlled trial, 10 patients with OSF received a topical application 
of aloe vera gel (5mg applied 3 times daily to the buccal mucosa for 3 months) and were 
compared with 10 patients who received antioxidant capsules twice daily  28. In the 
experimental arm a 55%-65% reduction in burning sensation was noted when measured by a 
VAS scale. An improvement of 4.3-7mm in mouth opening was also reported.  
In a further randomised trial aloe vera gel was tested as an adjunct to medicinal (injection of a 
mixture of hyaluronidase and dexamethasone) and surgical approaches in the treatment of 
OSF 29. 60 patients were randomized into the medicinal and surgical groups, and within each 
group (n=30), half received the gel treatment. Additional improvement in both mouth 
opening and burning sensation were found in those receiving the aloe vera. 
 Effect of curcumin was tested in a randomised clinical trial in comparison to intra-
lesional steroid injections 30. The experimental arm (n=20)  received curcumin by oral 
administration of 2 tablets of Turmix (each film-coated tablet containing 300 mg  C. longa 
and 5 mg piperine) given once daily for a period of 3 months.  The control group received 
weekly intralesional  injections of 4 mg dexamethasone and 1500 iu of hyaluronidase. Mouth 
opening improved by 3 mm and the burning sensation improved completely in the curcumin 
group.  
 In a further RCT, a combination of curcumin and turmeric oil was tested by Das et al  
31
. Curcumin 1g per day was given in two divided doses, and a second group was given 12 
drops of turmeric acid to hold in mouth and swallow twice daily. A control group received 
multivitamins 500 mg twice daily. Patients were followed up monthly for 6 months. 
Complete relief of pain was reported in both experimental groups after one month’s 
treatment. A mean increased mouth opening of 0.87 cm was noted in both test groups 
significantly better compared with 0.18 cm in the control group..  
 
Immunomodulation using steroid preparations (topical and intra-lesional) 
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Various steroid preparations have been tested in an attempt to reduce profibrotic 
inflammation, and to enhance pro-fibrolytic immune-mediated pathways. In Indian studies, 
the use of steroids has been the most widely adopted approach for the treatment of OSF. The 
agents used have included betamethasone and triamcinolone acetonide as topical agents 11, 13, 
and hydrocortisone, methylprednisolone (20mg/0.5ml), dexamethasone, triamcinolone 
diacetate used for intra lesional injections 32, 12, 33, 8, 34, 35, 11, 13, 36, 37, 38, 39, 30, 20, 29, 24 40. Topical 
steroids (see Table 1) may relieve the early symptoms of inflammation and mucositis 
experienced by OSF subjects but have not shown any efficacy in reversing fibrosis. The 
authors report better results derived by intra-lesional injections, although it is alleged that 
repeated needle-stick trauma may cause additional scar tissue formation 8. 
 
Other immunomodulators  
Levamisole was tested in one RCT. The 45 participants reported by Jirge et al16. were 
divided equally between three study groups: oral levamisole (group I), an oral antioxidant 
[Antoxid®] – containing beta carotene, selenium oxide, zinc sulphate, manganese and 
copper](group II), or oral levamisole with antioxidant (group III).  On conclusion of the 
intervention period (approximately 15 weeks) there were improvements of mouth opening of 
7.1%, 6.7% and 8.0% in groups I, II and III, respectively.  These gains were maintained on 
further evaluation two months later. There was also a significant reduction in burning 
sensations in all study groups.  
  
Probiotic agents, such as immunised cows milk prepared by immunization of cows with 
human intestinal bacteria has been proposed as a method of immunomodulation. The authors 
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reported an increase on mouth opening in 69% of their subjects by >3 mm but this study has 
not been reproduced elsewhere41. 
 
Biogenic stimulators 
Aqueous extracts of human placentas have been used as a biogenic stimulator in several 
studies as a way of altering collagen synthesis 34, 35, 42, 43, 14 (see Table 1). 
 
Cytokines 
Among an immigrant Asian population in London, interferon gamma (IFNγ) was used to  
downregulate fibroblast proliferation as a treatment of OSF 44. 15 injections of 50 ug IFNγ 
was injected intralesionaly twice a week for 8 weeks and followed up to 6 months. The 
authors noted some improvement in OSF but the study was uncontrolled and was confounded 
by simultaneous use of physiotherapy. 
 A COX-2 inhibitor has been tried as a mucoadhesive film (valdecoxib) applied to the 
buccal mucosae in a pilot study as a proof of concept to use long acting topical agents45.  
 
Enzymes and fibrinolytic agents 
Proteolytic enzymes are known to breakdown the inappropriate connective tissue fibrosis.  
Cross-linking of collagen has been observed in OSF as a pathogenic mechanism contributing  
to the limitation of mouth opening in advanced cases. Several agents have been tested to 
promote fibrolysis, the most common of which is hyaluronidase 34, 35, 11, 13, 32, 29, 40  which, 
when injected, is known to breakdown the intercellular cement substances. Krishnamoorthy 
et al in Bangalore, India between 2002 and 2004 enrolled 50 patients randomized to two 
groups. Group 1 received an oral tablet of colchicine 0.5 mg twice daily and 1500 IU  
hyaluronidase mixed in 1 ml lignocaine (0.5 ml) injected intralesionally into the buccal 
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mucosa. Group 2 received hyuluronidase as in group 1 and in addition 0.5 ml of 
hydrocortisone acetate 25mg/ml to each buccal mucosa once a week for 12 weeks. Both 
groups received habit intervention. Significant improvement of symptoms were reported in 
both study groups46. Other agents include papain as a topical agent, and both collagenase  and 
chymotrypsin used as intralesional injections.  Collagenase is a lysosomal enzyme capable of 
degrading various esters that are involved in cross linking of the cement substance. 
Chymotrypsin is a proteolytic enzyme (Serine protease) acting in the digestive systems of 
many organisms. It facilitates the cleavage of peptide bonds. Some improvement of 
symptoms have been reported by various Indian authors 14, 39, 37, 35  . 
46
 
Vasodilators 
The rationale for the use of a peripheral vasodilator, is based on the assumption that it may 
relax and dilate the blood vessels in the stromal tissues, ensuring greater blood supply to the 
ischemic tissues and helps the nutritional and therapeutic agents to reach the affected tissues. 
The agents tested include pentoxifylline 47, 48 , nylidrin hydrochloride 49, buflomedial 
hydrochloride 13 and Danxuan Koukang (DXKK) 50, and  isoxsuprine36 (see Table 1).  
 Pentoxifylline, generally marketed for intermittent claudication, is known to have a 
gamit of properties that may alter the course of wound healing. Connective tissue disorders 
may respond to pentoxifylline with an increase in fibroblast collagenases and decreased 
collagen, fibronectin, and glycosaminoglycan production. Fibroblast responsiveness to tumor 
necrosis factor is also diminished by this agent 51. Pentoxifylline was used in two RCTs47, 48 . 
In the earlier trial, twenty-nine participants were divided into two groups that took either oral 
pentoxifylline or multi-vitamins. All those enrolled completed the 7 month study period.  The 
authors reported statistically significant improvements in the oral pentoxifylline group (n=14) 
compared to controls with respect to both the objective criteria (mouth opening, tongue 
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protrusion and relief from circum-oral fibrotic bands) and the subjective criteria (intolerance 
to spices, burning sensations, tinnitus, difficulty in swallowing, and difficulty in speech).  
 A later study by Mehrotra et al 48, 32 patients were given pentoxifylline for a period 
of 7 months, administered for the initial 30 days at a reduced dosage of 400mg twice  daily 
and then increased to 400mg three times tablets daily for 6 more months as per the earlier  
study. The placebo group  (n=30) was given multivitamin therapy.  The authors reported 10 
mm improved mouth opening with pentoxifylline compared to 6 mm with multivitamins. 
 In a further study a vasodilator, isoxsuprine, combined with physiotherapy, was 
compared to intralesional injections of dexamethasone with hyaluronidase and physiotherapy 
or physiotherapy alone on the symptoms of OSF 40. The authors reported the outcome after 6 
weeks of treatment and then again at the end of the 4 months follow up period. Both 
isoxsuprine and dexamethasone with hyaluronidase treatments significantly alleviated 
burning sensation and increased mouth opening by approximate 3 mm, 
 
Evaluating outcome measures 
Outcome measures reported in intervention trials on OSF are highly variable both in the type 
and the manner in which they were measured. In terms of objective measures, mouth opening 
(generally measured as inter-incisal opening) appears to be the most frequently measured 
outcome across all studies, although the level of reliability (e.g. validation of measurements) 
is not clearly defined. Instruments have been introduced that enable the clinician to accurately 
measure the inter-incisal distance. Other objective measures include changes in tongue 
movement (ie ability to protrude), degree of suppleness of the tissues, amount of blanching of 
the mucosa, presence of ulceration/vesicle formation, and amount of dorsal tongue 
papillation, although the methodology for measuring these other objective outcomes is poorly 
defined in many research studies and are of questionable reliability. In terms of subjective 
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measures, oral burning/pain is the most consistently measured subjective outcome, although 
very few studies reported the outcome using validated pain assessment instruments, such as a 
visual analogue pain rating scale (VAS). Other subjective measures include change in taste, 
oral dryness, and ability to chew, swallow, or speak. None of the studies used validated 
instruments evaluating quality of life of subjects with OSF, nor could we find any such 
instruments in the published literature. 
 
Physical exercise  
Cox and Zoellner enrolled 54 Nepali subjects into 3 groups: physiotherapy, injections with a 
combination hyaluronidase/steroids, and a control group. After 4 months, subjective and 
objective measures were compared to baseline. The physiotherapy group showed a significant 
increase in opening but had no superior effect on subjective measures32.  
For subjects with advanced OSF ultrasound therapy has been tested. Ultrasonic tissue 
heating is likely to increase local tissue temperature, increased local circulation of blood flow 
and possible tissue disruption of cross linked collagen. Pal et al reported an improvement of 
symptoms in 50% of their cases when treated by ultrasonography 52.    (see Table 2) 
 
Surgical treatment 
There is an exhaustive literature on surgical excision of bands, coronectomy and temporal 
muscle myotomy to release the fibrosis among patients not responding to conservative 
treatment or for advanced cases of OSF (Table 3). Instead of cold knife surgery the use of 
CO2 or KTP-532 or Diode laser  53 has also been reported for removal of fibrous bands. 
 Reconstruction with tissue flaps from various donor sites has been undertaken. It is not  
intended to review this literature in full as surgical interventions are covered elsewhere 13, 54. 
Various grafting techniques include the use of buccal fat pads,  tongue flaps, nasolabial flap, 
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and radial forearm flaps 55, 38, ,56, 57, 58,59, 60, 61, 62, 63, 59, 64, 56, 65, 66,67, 68, 69, 70, 68, 63. Artificial grafts 
that promote tissue regeneration have also been advocated in reconstruction of defects 
following surgery 71.  Continued physical therapy is advocated to reduce relapse following 
surgery. A randomized trial comparing a nasolabial flap with a radial free forearm flap was 
reported recently 72. 60 patients with OSF were recruited, 30 to each arm of the study. Stick 
exercises were encouraged for all patients from day 1 following surgery. None of the patients 
experienced necrosis of flaps and results for the 50 subjects were available. Both surgical 
techniques achieved good mouth opening but average shrinkage of about 5 mm was noticed 
in patients in the late post operative period. Mean increase in mouth opening was greater in 
patients receiving the radial free forearm flap compared with nasolabial flap (18.96 mm vs 
15.16 mm). 
Randomized Controlled Studies 
A Cochrane review 73 and a later published  systematic review 74 identified three 
medical interventions with an RCT design  to study the effectiveness of systemic therapies on 
OSF: pentoxifylline 47, lycopene 20 and levamisole with anti-oxidants 16.  These trials were 
run at a single center, were randomized but the observers were not blinded in reporting 
outcomes. There was one other prospective controlled study that lacked randomization 37. 
Since the publication by Kerr et al 74 several  medical interventions with a RCT design have 
been added to the literature testing lycopene, colchicine and hyaluronidase 21, 46, aloe vera 28, 
29
,  and the vasodiators pentoxifylline 48, isoxsuprine40, and  Salvianolic acid 24   . Curcumin 
and turmeric oil 31 has also  been used in one open label trial. 
On the application of physical exercise and comparison of surgical techniques there is 
a single RCT in each category 32, 72.  
A working group of the WWOM V reanalyzed the published data from four RCTs 
(completed before 2011) using the GRADE criteria and identified significant limitations with 
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each trial and challenged the conclusions reached by the authors. The studies published after 
2011 appear to have similar limitations to these previously reported RCTs. 
 
Future studies 
Based on the extensive literature reviewed here the authors would like to propose 
potential therapies that need further study. It is important to bear in mind cost considerations 
of any proposed therapies in view of the socioeconomic status of the affected population in 
low to middle income countries. Taking into account the chronicity of the disease, patient 
compliance also may be sub-optimal for undergoing aggressive therapies. Naturally occurring 
compounds with anti oxidant properties eg. curcumin, aloe vera and tea pigments therefore 
have a great appeal. These agents in various formulations need to be tested in large clinical 
trials in Asia. 
When topically applied medications are used for treatment of OSF, poor permeation 
and absorption is likely and may limit efficacy. Recently developed novel muco-adhesive 
buccal films when tested in vitro appear to facilitate the delivery the drugs to local sites 
effectively 45.  
  Trials testing antioxidants have shown some improvement in both mouth opening 
and burning symptoms. Further trials are indicated in larger populations.  
Recently Clostridium histolyticum collagenases (Xiapex) has been licensed for the 
treatment of fibrotic conditions such as Dupuytren’s contracture. It contains collagenase 
isolated from the bacterium Clostridium histolyticum. The enzyme has a high affinity to 
digest collagen (particularly class 1 and 111) and to cleave insoluble triple helical collagen. A 
double-blind randomized study has confirmed its efficacy in Duputrene’s contracture 75. 
However, the cost of this new enzyme may preclude its availability in low-income countries.  
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Transforming growth factor β (TGFβ ) plays a specific role in regulation of ECM by 
regulating the synthesis and degradation of specific ECM components. Upregulation of TGF 
β  has been demonstrated in OSF and has been proposed to play a pivotal role in the 
aetiopathology 1. Aberrent expression of this growth factor has also been reported in keloids, 
atherosclerosis, pulmonary and liver fibrosis and scleroderma 76. Imatinib is thought to affect 
fibrotic pathways by selectively interferring with TGFβ signaling pathways 77. Imatinib has 
been used as an antifibrotic drug for experimental treatment of scleroderma 78 and may have a 
role in placebo-controlled studies in OSF. 
 Pirfenidone has well-established antifibrotic and anti-inflammatory properties in 
various in vitro systems and animal models of fibrosis. A number of cell-based studies have 
shown that pirfenidone reduces fibroblast proliferation, inhibits TGF β stimulated collagen 
production. Pirfenidone  has been evaluated in a phase 111 trial for patients with idiopathic 
pulmonary fibrosis (IPF).  Other potential candidates include Simtuzumab developed by 
Gilead Sciences, Inc. –(humanized monoclonal antibody targeting the human LOXL2 
protein). The LOX enzyme is known to be upregulated in OSF 79. Simtuzumab is currently 
being evaluated in a phase 11 trial for patients with IPF. A recent group has hypothesized that 
hyperbaric oxygen may contribute to treat OSF as it decreases the expression of hypoxia-
inducible factor  HIF and simultaneously increases the vascular VEGF expression and 
angiogenesis 80 
Recent reviews on molecular mechanisms underlying OSF have revealed possible molecular 
targets that may be used in interventions.92,93 Targeted therapies could be designed using 
these novel findings.  
 
Conclusions 
 
OSF remains refractory to most chemopreventive or other systemic medical therapies tried so 
far in the past 3 decades. Placebo-controlled controlled trials all show some improvement but 
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the sample sizes have been small and analyses of trial data have not been robust. More trials 
are needed before the benefit of these already tried out medicines can be confirmed. 
Furthermore, promising novel antifibrotic drugs used in other systemic conditions have not 
been tested in this population. 
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Table 1: Medical Interventions 
 
Group Rationale Examples of Interventions  Dosage /route references 
Nutrients, 
micronutrients  
 
 
 
 
 
 
Correct deficiency states 
and promote normal 
cellular processes 
present in health that 
help to protect against 
adverse events 
including 
carcinogenesis 
 Systemic Vitamins A, B complex, C, D & 
E plus minerals iron, zinc, 
magnesium and others given 
singly or in combination 
 
 
11
,
12
,
38
,
13
,
14
,
81
, 
16
 
Anti-oxidants Cells are protected 
against oxidative 
stress by interacting 
with an antioxidant 
 
 
Systemic 
Topical 
Glucosidorum tripterygii totorum, 
vitamins A & E, nicotinic acid 
 
36
 
Lycopene  Systemic;  
8 mg daily 
20
,
21
  
Tea pigments  22 
Salvianolic acid   23  
Aloe Vera 5mg applied 3 
times daily 
28
, 
29
 
Curcumin     300 mg  C. 
longa and 5 mg  
piperine  or 1g 
per day or 
    1g per day  
30
,
31
  
Spirulina 500 mg twice 
daily 
25
, 
26
,
27
 
Biogenic 
stimulation 
Homograft stimulates 
favourable metabolic 
processes that promote 
non-fibrotic tissue 
regeneration 
Intralesional 
injections 
Placental extract  43,34, 35, 42, 14 
Proteolytic enzymes Proteolytic enzymes 
breakdown the 
inappropriate 
connective tissue 
fibrosis 
Intralesional 
injections 
Papain (cysteine protease) with 
keratolytic action of urea: 
 
14
 
Collagenase   37, 39 
Hyaluronidase     1500 IU  mixed 
in 1 ml 
lignocaine 
34
, 
35
, 
11
, 
13
, 
32
, 
33
, 
46
 
Chymotrypsin   35 
Immune modulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immune modulation that 
diminishes pro-
fibrotic inflammation 
and enhances pro-
fibrolytic immune-
mediated pathways 
Topical  Corticostero
id 
 
Betamethasone Topical 11 
Triamcinolone 
acetonide 
Topical 13 
Intralesional 
injections 
Corticostero
id 
Dexamethasone  34, 35, 11, 13, 36 
Triamcinolone 
diacetate 
 
37
, 
11
, 
38
, 
39
, 
33
 
Methylprednisolo
ne 
 20mg/0.5ml 8 
Betamethasone      0.5 ml of  4 
mg/ml 
20
 
Hydrocortisone      0.5 ml of 
25mg/ml 
32
, 
12
, 
33
, 
46
 
Other Interferon gamma 
(IFN-γ) 
     Intra-
lesional 50 ug 
twice a week 
44
 
  Colchicine 0.5 mg twice 46 
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daily  
Systemic Levamisole  16 
Cows milk immunised with 
multiple human intestinal 
bacteria 
 
41
 
Promotion of blood 
flow 
Promote blood flow  to 
ischaemic tissues via 
multiple mechanisms 
including 
vasodilatation and 
mild anti-coagulant 
effects with other 
biological actions 
including 
immunomodulation 
and anti-oxidant 
functions 
Systemic Pentoxifylline 400mg bd or 
tds 
47
 
Isoxysuprine  40 
Nylidrin Hydrochloride  49 
Buflomedial hydrochloride  13,  
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Table 2: Physical Therapy and Surgical Interventions 
 
Group Rationale Examples of Interventions  references 
Physical therapy  Modify tissue remodelling 
through promotion of 
physical movements 
and localised heat  
Physiotherapy  Physical exercise regimen 
(including post-surgery) 
13
,  
32
 
Splints or other devices (including 
post-surgery) 
82
,
83
,
84
, 
85
 
Microwave diathermy 86,14   
 
Group Rationale Examples of Interventions  references 
Surgical  Interventions 
For advanced cases with severe limitation in 
opening, to release fibrous banding. 
Laser excision  87, 83, 53, 88, 89 
Coronoidectomy 
and muscle 
myotomy 
 
90
,
68
 
Excision & flap 
procedures 
Buccal fat pad 91, 92, 57, 58,59 
Tongue flap 55, 60 
Nasolabial flap 61, 62, 72,63, 59 
Superficial temporal fascia flap 64 
Forearm free flap 56, 65, 66,67, 68 
Palatal island flap 69 
Anterolateral thigh flap 70, 68 
Platysma myocutaneous muscle flap 63 
Excision and 
grafts/stents 
Split thickness skin graft 93,13,94 
Amnion graft 13 
Artificial dermis graft 71 
Collagen membrane 95 
Stents 84, 94 
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Statement of clinical relevance 
 
The management options for oral submucous fibrosis remain  unclear.  No single effective therapy 
has been described. This review identifies gaps in our knowledge to encourage further research to  
help in the development of  targeted therapies. 
 
